A composition with hangover-relieving and liver-protecting effects, its preparation method and applications

Abstract

The present invention relates to the field of pharmaceutical technology, and specifically relates to a composition with the functions of relieving hangover and protecting the liver, and its preparation method and application. The composition includes the following components in parts by weight: 55-75 parts of puerarin, 20-40 parts of dihydromyricetin, 10-20 parts of myricetin, 6-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3'-hydroxypuerarin, 20-30 parts of 3'-methoxypuerarin, 4-10 parts of vitexin, 4-10 parts of kaempferol, and 2-6 parts of quercetin. The composition has the functions of antioxidation, relieving hangover and protecting the liver, can significantly improve the drunken state, shorten the drunken time, and promote the metabolism of alcohol in the body.

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to a composition with alcohol sobering and liver protecting effects, and a preparation method and application thereof. Background Art

[0002] The liver is an organ in the human body that detoxifies and metabolizes, and can break down alcohol. Most non-nutritional substances are broken down by the liver, and toxic substances are metabolized into non-toxic or low-toxic substances and excreted from the body. There are many reasons for liver damage, such as excessive alcohol, drugs or other toxic substances, and the degree of damage is related to time, dosage, toxicity and other conditions. Alcoholic liver damage is caused by long-term and heavy drinking, involving a series of liver injuries, from fatty liver to alcoholic, including early-stage fatty degeneration, alcoholic hepatitis, cirrhosis, and even advanced liver cancer.

[0003] The pathogenesis of alcoholic liver injury has been studied by a large number of scholars at home and abroad. After absorbing a large amount of alcohol, the dynamic balance of oxidants and antioxidants in the liver during the alcohol metabolism process is broken, resulting in the generation of "oxidative stress" pathological reactions; various normal metabolisms of the liver, such as lipid metabolism, protein metabolism and sugar metabolism, are disordered, leading to aggravated liver damage; after drinking alcohol, based on the "intestinal flora-intestine-liver axis" pathway, endotoxin enters the blood and activates liver macrophages, releasing a large number of cytokines and inflammatory factors, triggering liver inflammation; multiple cell signal transduction pathways are activated, autophagosomes and lysosomes are formed in large quantities, prompting apoptosis and autophagy of liver cells.

[0004] At present, anti-inflammatory and liver-protecting drugs, corticosteroids, and anti-liver fibrosis drugs are the main drugs for drug treatment on the market, and their therapeutic effects are limited. Even long-term use can easily cause new liver damage. Therefore, it is urgent to find safe, effective, and non-toxic alternative drugs. At present, a large number of studies have shown that Chinese medicine has great medicinal value in sobering up and protecting the liver. For example, Chinese invention patent application CN101785515A discloses a production method of wood honey sobering up tea, which solves the problem that the traditional drinking water, tea, and vinegar methods are slow to sober up, and the natural sobering drugs of kudzu root and kudzu flower have weak spleen and stomach functions and are not pure enough in medicinal properties. It is suitable for drinking and drunk people to soak; Chinese invention patent application CN106692342A discloses a sobering up Chinese medicine composition and application, which is composed of an ethanol extract of Hovenia dulcis, an ethanol extract of kudzu flower, and an ethanol extract of kudzu root. However, the above patent application has problems such as inconvenience in taking, large dosage, and the effect needs to be further improved. Summary of the invention

[0005] In view of the prior art, the present invention provides a composition with the functions of relieving hangover and protecting the liver, its preparation method and application. The composition with the functions of relieving hangover and protecting the liver can effectively slow down and protect the liver damage caused by alcohol, and has the advantages of convenient administration, small dosage and good effect.

[0006] To achieve the above-mentioned invention purpose, the technical solution of the present invention is as follows:

[0007] The first aspect of the present invention relates to a composition with the functions of relieving hangover and protecting the liver. The composition includes, by weight: 55-75 parts of puerarin, 20-40 parts of dihydromyricetin, 10-20 parts of myricetin, 6-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3'-hydroxypuerarin, 20-30 parts of 3'-methoxypuerarin, 4-10 parts of vitexin, 4-10 parts of kaempferol, and 2-6 parts of quercetin.

[0008] Preferably, the composition includes, by weight: 60-75 parts of puerarin, 25-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3'-hydroxypuerarin, 20-28 parts of 3'-methoxypuerarin, 6-10 parts of vitexin, 6-10 parts of kaempferol, and 3-6 parts of quercetin.

[0009] Preferably, the composition includes, by weight: 60-70 parts of puerarin, 30-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-20 parts of 3'-hydroxypuerarin, 20-25 parts of 3'-methoxypuerarin, 6-8 parts of vitexin, 8-10 parts of kaempferol, and 4-6 parts of quercetin.

[0010] Preferably, the composition includes, by weight: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3'-hydroxypuerarin, 25 parts of 3'-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0011] Preferably, the mass ratio of puerarin to dihydromyricetin is 1.5-3.5.

[0012] Preferably, the mass ratio of 3'-hydroxypuerarin to 3'-methoxypuerarin is 0.5-1.

[0013] The second aspect of the present invention relates to a preparation method of the above-mentioned composition with the functions of relieving hangover and protecting the liver. The preparation method includes the following steps: mixing the formula amounts of puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin to obtain the composition.

[0014] The third aspect of the present invention relates to the application of the above-mentioned composition with the effect of relieving alcohol and protecting the liver in the preparation of products for antioxidant, relieving alcohol and sobering up, and protecting the liver.

[0015] Preferably, the product is a medicine or a food.

[0016] Preferably, the dosage form of the product is a solution, a syrup, a tablet, a pill, a cream, a plaster, a decoction extract, a granule or a capsule.

[0017] Advantages of the present invention: (1) The composition can prolong the sleep time of mice after alcohol administration and shorten the sleep time of mice after getting drunk, that is, the righting reflex time of mice becomes shorter; (2) The composition promotes the liver's metabolism of alcohol and improves the effects of alcohol on the activities of MDA, SOD, and GSH-Px, reducing their activity levels in the serum; (3) When the composition provided by the present invention has a specific component composition and a specific dosage ratio, the effect is significantly improved. The composition can be effectively used for antioxidant, relieving alcohol and sobering up, and preventing or treating alcoholic liver injury. Detailed implementation manners

[0018] To clarify the purpose, technical solution and advantages of the present invention, the following further details the present invention in combination with specific embodiments. In order to make the technical means, creative features, achieved purposes and effects of the present invention easy to understand, the following further clarifies the present invention in combination with specific embodiments. However, the following embodiments are only the preferred embodiments of the present invention, not all of them. Based on the embodiments in the implementation manners, other embodiments obtained by those skilled in the art without creative labor all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are all conventional operating methods, and the equipment used is all conventional equipment. The equipment materials used in each embodiment are the same. The present invention does not limit the source of the raw materials used. Unless otherwise specified, the raw materials used in the present invention are all ordinary commercially available products in the technical field, and the purity is above 98%. The raw material information in the formula of the present invention is shown in Table 1.

[0019] Table 1: Raw material information table in the formula of the present invention

[0020]

[0021] Example 1:

[0022] By weight, the formula is: 70 parts of puerarin, 20 parts of dihydromyricetin, 10 parts of myricetin, 6 parts of puerarin-4-β-glucoside, 15 parts of 3'-hydroxypuerarin, 20 parts of 3'-methoxypuerarin, 4 parts of vitexin, 4 parts of kaempferol, and 2 parts of quercetin.

[0023] Preparation method: Mix puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin in the formula amounts to obtain the composition.

[0024] Example 2:

[0025] By weight, the formula is: 55 parts of puerarin, 25 parts of dihydromyricetin, 10 parts of myricetin, 10 parts of puerarin-4-β-glucoside, 20 parts of 3'-hydroxypuerarin, 25 parts of 3'-methoxypuerarin, 6 parts of vitexin, 6 parts of kaempferol, and 4 parts of quercetin.

[0026] Preparation method: Mix puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin in the formula amounts to obtain the composition.

[0027] Example 3:

[0028] By weight, the formula is: 60 parts of puerarin, 35 parts of dihydromyricetin, 15 parts of myricetin, 8 parts of puerarin-4-β-glucoside, 15 parts of 3'-hydroxypuerarin, 30 parts of 3'-methoxypuerarin, 8 parts of vitexin, 10 parts of kaempferol, and 6 parts of quercetin.

[0029] Preparation method: Mix puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin in the formula amounts to obtain the composition.

[0030] Example 4:

[0031] By weight, the formula is: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3'-hydroxypuerarin, 25 parts of 3'-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0032] Preparation method: Mix puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin in the formula amounts to obtain the composition.

[0033] The formulas of Examples 1-4 are shown in Table 2 by weight.

[0034] Table 2: Formulas of Examples 1-4

[0035]

[0036] Comparative Example 1:

[0037] By weight parts, the formula is: 50 parts of puerarin, 45 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3'-hydroxypuerarin, 25 parts of 3'-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0038] The difference from Example 4 lies in the dosages of puerarin and dihydromyricetin and their mass ratio. In Example 4, puerarin is 65 parts and dihydromyricetin is 30 parts, and their mass ratio is 2.17. While in Comparative Example 1, puerarin is 50 parts and dihydromyricetin is 45 parts, and their mass ratio is 1.11.

[0039] The preparation method is the same as that of Example 4.

[0040] Comparative Example 2:

[0041] By weight parts, the formula is: 95 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3'-hydroxypuerarin, 25 parts of 3'-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0042] The difference from Example 4 is only that puerarin is replaced with an equal amount of dihydromyricetin, and the rest is the same as Example 4.

[0043] Preparation method: Mix the formula amounts of dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin to obtain the said composition.

[0044] Comparative Example 3:

[0045] By weight parts, the formula is: 95 parts of puerarin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3'-hydroxypuerarin, 25 parts of 3'-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0046] The difference from Example 4 is only that dihydromyricetin is replaced with an equal amount of puerarin, and the rest is the same as Example 4.

[0047] Preparation method: Mix the formula amounts of puerarin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin to obtain the said composition.

[0048] Comparative Example 4:

[0049] By weight parts, the formula is: puerarin 65 parts, dihydromyricetin 30 parts, myricetin 18 parts, puerarin-4-β-glucoside 12 parts, 3'-hydroxypuerarin 30 parts, 3'-methoxypuerarin 15 parts, vitexin 6 parts, kaempferol 8 parts, quercetin 4 parts.

[0050] The difference from Example 4 lies in the dosages of 3'-hydroxypuerarin and 3'-methoxypuerarin and their mass ratio. In Example 4, 3'-hydroxypuerarin is 20 parts, 3'-methoxypuerarin is 25 parts, and their mass ratio is 0.8, while in Comparative Example 4, 3'-hydroxypuerarin is 30 parts, 3'-methoxypuerarin is 15 parts, and their mass ratio is 2.

[0051] The preparation method is the same as that of Example 4.

[0052] Comparative Example 5:

[0053] By weight parts, the formula is: puerarin 65 parts, dihydromyricetin 30 parts, myricetin 18 parts, puerarin-4-β-glucoside 12 parts, 3'-hydroxypuerarin 45 parts, vitexin 6 parts, kaempferol 8 parts, quercetin 4 parts.

[0054] The difference from Example 4 is that 3'-methoxypuerarin is replaced with an equal amount of 3'-hydroxypuerarin, and the rest is the same as Example 4.

[0055] Preparation method: Mix the formula amounts of puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-hydroxypuerarin, vitexin, kaempferol, and quercetin to obtain the composition.

[0056] Comparative Example 6:

[0057] By weight parts, the formula is: puerarin 65 parts, dihydromyricetin 30 parts, myricetin 18 parts, puerarin-4-β-glucoside 12 parts, 3'-methoxypuerarin 45 parts, vitexin 6 parts, kaempferol 8 parts, quercetin 4 parts.

[0058] The difference from Example 4 is that 3'-hydroxypuerarin is replaced with an equal amount of 3'-methoxypuerarin, and the rest is the same as Example 4.

[0059] Preparation method: Mix the formula amounts of puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3'-methoxypuerarin, vitexin, kaempferol, and quercetin to obtain the composition.

[0060] Experimental instruments: Infinite M200 PRO microplate reader, centrifuge, balance, cell disruptor, constant temperature water bath, scalpel, CO 2 incubator.

[0061] Experimental materials: SPF-grade Kunming mice, CCK-8 assay kit, RPMI1640 culture medium, and HepG2-human hepatoma cells were purchased from Wuhan Punosai Life Science Co., Ltd. MDA kit, SOD kit, and GSH-Px kit were all purchased from Nanjing Jiancheng Bioengineering Institute.

[0062] Experimental example 1:

[0063] In vitro antioxidant experiment: Determination of DPPH and ABTS+ antioxidant capacities. Antioxidant assays were performed using DPPH and ABTS working fluid reagents. The freeze-dried drug powders of each group were serially diluted to 0.025 mg / mL, 0.050 mg / mL, 0.100 mg / mL, 0.200 mg / mL, 0.400 mg / mL, 0.800 mg / mL, and 1.000 mg / mL. Calculate their antioxidant capacities to obtain the IC 50 value.

[0064] The IC 50 (mg / mL) values of the DPPH and ABTS+ antioxidant capacities of each group are shown in Table 3.

[0065] Table 3: IC 50 values of antioxidant activities of each group (unit: mg / mL)

[0066]

[0067] The results show that within the concentration range of 0.025 - 1.000 mg / mL, there is good antioxidant activity. Among them, compared with Comparative Examples 1 - 6, the IC 50 of Examples 1 - 4 is smaller, and the antioxidant activity is better.

[0068] Experimental example 2:

[0069] Cell viability experiment: Use CCK8 to measure the cell viability of different groups of HepG2 cells after drug administration and calculate the relevant cell viability IC 50 value.

[0070] Modeling was performed using different concentrations of ethanol: 1%, 2%, 3%, 4%, 5%, and 6% ethanol to screen for the appropriate modeling dose.

[0071] Take HepG2 cells and inoculate them at 2×10 5 / mL into 12-well plates, 2 mL per well, and culture for 24 h. After modeling with ethanol (final concentration of 4%) for 16 hours, add drugs of different groups for intervention treatment, collect the cells, and measure the biochemical indices of MDA, SOD, and GSH-Px.

[0072] Cell viability assay: The concentration range was controlled at 0 - 3.2 mg / mL, and the CCK8 reagent was used to calculate the IC of cell viability 50 value (mg / mL). The results are shown in Table 4.

[0073] Table 4: IC of cell viability in each group 50 value (unit: mg / mL)

[0074]

[0075] According to the above results, compared with Comparative Examples 1 - 6, Examples 1 - 4 had higher concentrations, stronger cell viability, and lower toxicity.

[0076] Establishment of an ethanol-induced acute alcoholic liver injury model in HepG2 cells: The CCK8 reagent was used to calculate cell viability (%). The ethanol concentrations are shown in Table 5. When the alcohol concentration was in the range of 0 - 6%, the cell survival rate decreased in a dose-dependent manner. As the alcohol concentration further increased to 5%, the cell viability decreased to 36.91%. At this time, alcohol showed a strong killing effect on the cells, with severe oxidative damage in the cells, leading to a large number of cell apoptoses. Considering comprehensively, 4% was selected as the appropriate alcohol concentration to establish an alcohol-induced oxidative damage model in HepG2 cells for subsequent experiments.

[0077] Table 5: Ethanol concentration screening experiment for cell viability assay

[0078]

[0079] The antioxidant damage ability of HepG2 cells was measured using SOD, MDA, and GSH-Px kits, and the results are shown in Table 6.

[0080] Table 6: Results of the effect on the antioxidant damage ability of HepG2 cells

[0081]

[0082] Note: Compared with the blank group, # P < 0.05; compared with the model group; * P < 0.05, ** P < 0.01; compared with Example 4, □□P < 0.01 between each administration group.

[0083] Compared with the blank group, the activities of SOD and GSH-Px in the model group were significantly decreased ( P < 0.05), and the content of MDA was significantly increased ( P < 0.05), indicating successful model establishment. Compared with the model group, the drugs in Examples 1 - 4 and Comparative Examples 1 - 6 groups had positive regulatory effects on the activities of SOD and GSH-Px and the content of MDA, and the differences were statistically significant ( P< 0.05) or significantly different ( P < 0.01). Compared with Example 4, the effects of Examples 1-3 and Example 4 are equivalent, and both are significantly superior to the effects of the drugs in Comparative Examples 1-6. The provided composition of the present invention has a better positive regulatory effect on the activities of SOD and GSH-Px and the content of MDA.

[0084] Experimental Example 3:

[0085] Animal experiment: The compositions with the effects of relieving alcohol and protecting the liver prepared in Examples 1-4 and the compositions prepared in Comparative Examples 1-6 were respectively administered to KM mice, and a blank group of mice was set up for the experiment. Before the experiment, the drugs in Examples 1-4 and Comparative Examples 1-6 were dissolved in physiological saline.

[0086] The groups were divided into a blank group, a model group, and a drug administration group (Examples 1-4, Comparative Examples 1-6). Among them, the blank group and the model group were intragastrically administered with 5 mL / kg of physiological saline. Each example group and comparative example group were continuously intragastrically administered with the corresponding composition for 21 days, once a day, and the administration dose was 11 g / kg•bw. Intragastric administration was carried out according to 5 mL / kg body weight. Administration was carried out in the morning on the 22nd - 28th days, and 50% alcohol was intragastrically administered in the afternoon. The alcohol intragastric administration dose was gradually increased from 4 mg / g to 6 mg / g, and the body weight was weighed every three days to adjust the administration dose. After the last administration, all mice in each group were strictly fasted but not water-deprived for 16 h, blood was taken by eye socket puncture, the liver was dissected and removed, and the data was recorded and relevant indicators were detected.

[0087] Drunken sleep experiment: Record the activities of each mouse after alcohol administration on the 28th day. The indicators for sleep or drunkenness were that the mouse crawled unsteadily, moved slowly, and closed its eyes and was lazy to move. The indicators for waking up or sobering up were that the mouse moved freely, its limbs were flexible, and its spirit returned to normal. Record the time of falling asleep and waking up of the mouse, and calculate the sleep tolerance time (i.e., the time from alcohol administration to falling asleep) and the duration (i.e., the time from falling asleep to waking up), unit: min.

[0088] Detection of antioxidant indexes in mouse liver: Take an appropriate amount of liver for homogenization, 10% liver tissue homogenate, and detect the contents of MDA, SOD, GSH-Px, etc. in the mouse liver according to the operation of the kit.

[0089] The results of the drunken sleep experiment are shown in Table 7.

[0090] Table 7: Sleep tolerance time after alcohol intragastric administration on the 28th day (min, n = 10, mean ± standard deviation)

[0091]

[0092] Note: Compared with the blank group, ##P < 0.01; compared with the model group; *P < 0.05, **P < 0.01; compared with Example 4, ○P < 0.05, ○○P < 0.01 between each dosing group.

[0093] In the observation of mice after alcohol administration on the 28th day, the compositions with hangover and liver protection effects prepared in Examples 1-4 had a more significant effect on the sleep tolerance time and sleep duration of mice than those in Comparative Examples 1-3.

[0094] The detection results of antioxidant indexes in the livers of mice are shown in Table 8.

[0095] Table 8: Effects on the contents of related components in the livers of mice (mean ± standard deviation, n = 10)

[0096]

[0097] Note: Compared with the blank group, # P < 0.05; compared with the model group; *P < 0.05, **P < 0.01; compared with Example 4, ○P < 0.05, ○○P < 0.01 between each dosing group.

[0098] The content of MDA is an important parameter reflecting the potential antioxidant capacity of the body, which can reflect the rate and intensity of lipid peroxidation in the body and can also indirectly reflect the degree of tissue peroxidation damage. The drugs in Examples 1-4 and Comparative Examples 1-6 can all reduce the MDA content in model mice, but the degree of reduction in MDA content in Examples 1-4 is significantly better than that in Comparative Examples 1-6. SOD and GSH-Px are important antioxidant enzymes in the body. Through their cooperative action, they convert reactive oxygen species into harmless substances to protect cells from oxidative damage. At the same time, they can also be used as indicators of the degree of oxidative stress in the body to reflect the health status of the organism. It can be seen from the table that the drugs in Examples 1-4 and Comparative Examples 1-6 can all increase the SOD and GSH-Px contents in model mice, but the effect of Examples 1-4 is significantly better than that of the Comparative Examples 1-6 group.

[0099] From the above data, it can be seen that the composition in the present invention can significantly improve the effects of alcohol on the drunkenness and sobering time of mice, and can also significantly improve related biochemical indexes, such as the oxidation indexes of MDA, SOD, and GSH-Px in the liver, proving that the composition has the activity of anti-alcoholic liver injury and its possibility as an anti-alcoholic liver injury. The effect of the composition in the examples of the present invention is significantly better than that of each comparative example, and the composition provided by the present invention can more effectively prevent or reduce the damage of alcohol to the liver.

[0100] It can be seen from this that the composition described in the present invention can, to a certain extent, prevent or reduce the damage of alcohol to the liver.

[0101] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than limiting the protection scope of the present invention. Any simple modification or equivalent replacement made by those of ordinary skill in the art to the technical solution of the present invention shall not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition having the effects of sobering up and protecting the liver, characterized in that: The composition is composed of the following components by weight: 55-75 parts of puerarin, 20-40 parts of dihydromyricetin, 10-20 parts of myricetin, 6-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3′-hydroxypuerarin, 20-30 parts of 3′-methoxypuerarin, 4-10 parts of vitexin, 4-10 parts of kaempferol, and 2-6 parts of quercetin; wherein, The mass ratio of puerarin to dihydromyricetin is 1.5-3.5; The mass ratio of the 3'-hydroxypuerarin to the 3'-methoxypuerarin is 0.5-1.

2. The composition having alcohol sobering and liver protecting effects according to claim 1, characterized in that: The composition consists of the following components in parts by weight: 60-75 parts of puerarin, 25-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3′-hydroxypuerarin, 20-28 parts of 3′-methoxypuerarin, 6-10 parts of vitexin, 6-10 parts of kaempferol and 3-6 parts of quercetin.

3. The composition having alcohol sobering and liver protecting effects according to claim 1, characterized in that: The composition consists of the following components in parts by weight: 60-70 parts of puerarin, 30-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-20 parts of 3′-hydroxypuerarin, 20-25 parts of 3′-methoxypuerarin, 6-8 parts of vitexin, 8-10 parts of kaempferol and 4-6 parts of quercetin.

4. The composition having the effects of sobering up and protecting the liver according to claim 1, characterized in that: The composition consists of the following components in parts by weight: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol and 4 parts of quercetin.

5. The method for preparing the composition having alcohol sobering and liver protecting effects according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: mixing the formulated amounts of puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin to obtain the obtained product.

6. Use of the composition with alcohol sobering and liver protecting effects according to any one of claims 1 to 4 or the composition with alcohol sobering and liver protecting effects obtained by the preparation method according to claim 5 in the preparation of drugs for sobering up, sobering up, and protecting the liver.

7. The use according to claim 6, characterized in that: The dosage form of the medicine is solution, syrup, tablet, pill, cream, plaster, decoction, granule or capsule.

Images